This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Wolf Haldenstein Announces Investigation Of Sarepta Therapeutics, Inc.,

Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the securities of Sarepta Therapeutics, Inc., (NASDAQ:SRPT) between July 24, 2013 and November 12, 2013.

The complaint alleges that during the Class Period, certain of the Company’s officers and directors violated federal securities laws by making false and misleading statements concerning the Company’s lead therapeutic candidate for the treatment of Duchenne muscular dystrophy, eteplirsen.

Specifically, the Complaint alleges that multiple misleading statements were made concerning: (1) the prospects of the Food and Drug Administration's ("FDA") acceptance for consideration of a New Drug Application ("NDA") for eteplirsen based on Sarepta's Phase IIb study data set, and (2) the significance of the Phase IIb data set.

On November 12, 2013, Sarepta disclosed that the FDA informed the Company that its announced NDA filing for eteplirsen was premature. On this news, Sarepta's stock price collapsed from its closing price of $36.56 per share on November 11, 2013 to $13.16 per share on November 12, 2013.

If you purchased Sarepta common stock during the Class Period, you may, no later than March 28, 2014, request that the Court appoint you as lead plaintiff of the class.

If you are a shareholder of Sarepta Therapeutics, Inc., (NASDAQ:SRPT) with a loss of $75,000 or more and would like additional information concerning your rights in this matter, please contact us at:

Gregory M. Nespole or Patrick DonovanWolf Haldenstein Adler Freeman & Herz LLP270 Madison AvenueNew York, New York 10016

Phone Numbers:(800) 575-0735(212) 545-4600

Please visit the Wolf Haldenstein website ( http://www.whafh.com) for more information about the firm.

Wolf Haldenstein did not file the original complaint against Sarepta Therapeutics, Inc.

Email:

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,067.56 -30.89 -0.18%
S&P 500 2,002.28 -1.09 -0.05%
NASDAQ 4,598.1880 +17.9170 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs